105 HIGH RESPONSE RATE FOR AZACITIDINE-LENALIDOMIDE (VI-LEN) COMBINATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - VILEN-01 PROTOCOL UPDATE. (April 2015) - Mittelman, M.; Filanovsky, K.; Ofran, Y.; Raanani, P.; Braester, A.; Goldshmidt, N.; Kirgner, I.; Herishanu, Y.; Perry, C.; Oster, H.S.; ,